

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ONV-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Sheet 1 of 2

Group

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |    | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|----------|-------------|
|                     | AA |                 |      |      |       |          |             |
|                     | AB |                 |      |      |       |          |             |
|                     | AC |                 |      |      |       |          |             |
|                     | AD |                 |      |      |       |          |             |
|                     | AE |                 |      |      |       |          |             |
|                     | AF |                 |      |      |       |          |             |
|                     | AG |                 |      |      |       |          |             |
|                     | AH |                 |      |      |       |          |             |
|                     | AI |                 |      |      |       |          |             |
|                     | AJ |                 |      |      |       |          |             |
|                     | AK |                 |      |      |       |          |             |
|                     | AL |                 |      |      |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION              |                          |
|--|----|-----------------|------|--------|-------|----------|--------------------------|--------------------------|
|  |    |                 |      |        |       |          | YES                      | NO                       |
|  | AM |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AN |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AO |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AP |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | AQ |                 |      |        |       |          | <input type="checkbox"/> | <input type="checkbox"/> |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| AR | Ottaviani et al., "Simultaneous in vitro exposure to Glivec (formerly STI571), Apo2L/TRAIL and Interferon-alpha, with or without prior Ara-C treatment, Apo2L/TRAIL-induced cytotoxicity and apoptosis in BCR/ABL + leukemic blasts," Blood, Vol. 98(11), Part 2, pp. 265b-266b (2001) |
| AS | Marley et al., "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia," British Journal of Haematology 2002, Vol. 116(1), pp. 162-165 (2002)   |
| AT | "Chronic Myelogenous Leukemia and Investigational Treatment Strategies," Leukemia Insights, Online!, Vol. 6(3), pp. 1-8 (2001)   |

|          |                  |                 |            |
|----------|------------------|-----------------|------------|
| EXAMINER | /Abigail Fisher/ | DATE CONSIDERED | 10/14/2008 |
|----------|------------------|-----------------|------------|

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.F./

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| DA | Topaly et al., "Synergistic activity of STI571 with chemotherapeutic drugs and irradiation," Blood, Vol. 96(11), Part 1, p. 736a (2000)  |
| DB | Druker Brian J et al., "A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML)," Blood, Vol. 98(11), Part 1, pp. 845A-846A (2001)               |
| DC | Ruchatz et al., "Co-administration of STI571 and idarubicin increases the sensitivity to cytotoxic treatment in vitro and in vivo," Blood, Vol. 98(11), Part 1, pp. 101a-102a (2001)   |
| DD | Keating, "Leukemia: a model for drug development," Clinical Cancer Research, The American Association for Cancer Research, US, Vol. 3(12), Part 2, pp. 2598-2604 (1997)  |
| DE | Berman et al., "Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia," Blood, Vol. 77(8), p. 1666-1674 (1991)                          |
| DF | Rosee La et al., "Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective," Leukemia, Vol. 16(7), pp. 1213-1219 (2002) |
| DG |  |
| DH |  |
| DI |  |
| DJ |  |
| DK |  |
| DL |  |
| DM |  |
| DN |  |

EXAMINER

/Abigail Fisher/

DATE CONSIDERED

10/14/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.